Our Director of Product, Will K. shares his perspectives on different approaches to building AI-driven companies as part of the AI and data track at TechBio UK on 16 October.
Isomorphic Labs
Biotechnology Research
We are reimagining the entire drug discovery process from first principles with an AI-first approach.
About us
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.
- Website
-
https://www.isomorphiclabs.com/
External link for Isomorphic Labs
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
London, GB
Employees at Isomorphic Labs
Updates
-
Our General Counsel Sarah Korman joins The Association of the British Pharmaceutical Industry (ABPI)’s inaugural regulatory science conference on October 10th to reflect on regulatory challenges in the field of drug design and to share perspectives on how frameworks could evolve to keep pace with rapid innovation in this space.
-
Sergei Yakneen, Julien Herzen Jörn Jacobsen from our Swiss team share how the power of AI is applied to rational drug design at Isomorphic Labs. Join them at Forum EPFL 2024 on October 9th to learn more about our approach to reimagining drug discovery from first principles.
-
Our CTO Sergei Yakneen will deliver the keynote speech to close a day of engaging events and conversations at #TechBio UK: Frontiers of Discovery
#TechBio UK will be returning on 📅 16 October at 📍Kings Place ➡️ https://ow.ly/Iqh450TnRGs We look forward to a keynote from Sergei Yakneen, Chief Technology Officer, Isomorphic Labs 🙌 Don't miss out! Secure your spot now in the link above. Special thanks to our headline supporter Eli Lilly and Company and event supporters AstraZeneca, Citeline, Cooley LLP, HSBC Innovation Banking, Johnson & Johnson and LifeArc 👏
-
In the third of our ‘In Conversation’ film series, Research Investigators Catarina Santos, and Marcos Vinicius da Silva Santana discuss how we employ interdisciplinary ways of working in our mission to reimagine the entire drug discovery process with the power and pace of AI. At Isomorphic Labs, by bringing people from different backgrounds, perspectives and disciplines together as one team, we are better placed to tackle some of the most fundamental challenges in drug design. Interested in getting involved? Find our current openings on our website: bit.ly/3wuRQbL #AI #drugdiscovery
-
Our CTO Sergei Yakneen shares his vision on the potential for AI to improve our understanding of disease biology and scale rational drug design at Isomorphic Labs in the latest episode of AI Game Changers with EPFL AI Center:
💡In today's episode of AI Game Changers, we're talking with Sergei Yakneen, Chief Technology Officer at Isomorphic Labs who specializes in machine learning, product, life science and medical research. In this interview, Sergei Yakneen’s talks to us about applying machine learning to transform #drugdiscovery and #genomics. The discussion covers large-scale data analysis expertise and how intelligent systems have the potential to improve #healthcare and drive innovation in #biomedicalresearch and drug development. You can learn more about the amazing research at Isomorphic Labs 👉https://lnkd.in/eH5ry4uh 🎥 Stay tuned every week for more insights from brilliant minds behind the ground-breaking work and research that drive advancements in #AI and #machinelearning ! #EPFLAICenter #AIGameChangers #AI4Science #AI4Education #AI4Health #AI4Sustainability #AI4Society #EPFL
-
We are delighted that Catherine Tong has been recognised by MIT Technology Review as one of its Innovators Under 35 Asia Pacific. Throughout her career and since joining Isomorphic Labs in 2022 as a research scientist in the Machine Learning team, Catherine has been a pioneer in building innovative AI models to overcome many of the fundamental challenges in drug discovery and advance human health. Her meaningful contributions to the development of AlphaFold 3 as well as her work on improving the prediction of protein-ligand structures and confidence estimates have made a material impact on how Iso is advancing the drug design process. tr35.mittrasia.com
-
AlphaFold 3, jointly released with Google DeepMind, represents a watershed moment in our understanding of biomolecular systems to advance biology and drug design. Chief AI Officer Max Jaderberg recently sat down with Sai Balasubramanian, M.D., J.D. for Forbes to discuss how our scientists use this technology alongside other breakthrough ML models developed at Isomorphic Labs “to rationally develop therapeutics against targets that were previously difficult or deemed intractable to modulate.” Read more here: bit.ly/4d4mlFb
-
Congratulations to our CEO Demis Hassabis for being awarded a Leader on the #TIME100 AI List 2024 Read more here: https://lnkd.in/drFj6utT
TIME100 AI 2024: Demis Hassabis
time.com
-
Congratulations to the team at Google DeepMind on launching #AlphaProteo, an AI system that could improve our understanding of biological processes. This system advances biological and health research, by supporting scientists in their creation of novel proteins that successfully bind to target molecules. Our scientists at Isomorphic Labs are excited to explore this model in application to drug design.
Introducing AlphaProteo: an AI system for designing novel proteins that bind more successfully to target molecules. 🧬 This research could help deepen our understanding of fundamental biology. Here’s how: 🔵 Protein binders are essential tools in drug development and biotech. They’ve already demonstrated potential in binding cancer cells, blocking viral infections and more. 🔵 AlphaProteo managed to generate candidates with strong binding to 7️⃣ diverse proteins related to infection, cancer, inflammation, and autoimmune disease. 🔵 AI for protein design has great potential - but more work is needed. We’re improving AlphaProteo’s success rate and will continue working with scientists to develop a responsible offering for the community. Find out more ↓https://dpmd.ai/4geFM0L